Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether adding topical Cyclosporine A eye drops to standard treatment with Natamycin improves vision outcomes in patients with fungal keratitis, an infection of the cornea. This randomized, masked clinical trial compares low-dose 0.1% and higher-dose 2% Cyclosporine A against a placebo to see which works best as an additional therapy. The study aims to find out if early use of Cyclosporine A benefits mild to moderate fungal keratitis and which ulcer features predict the most improvement. Participants with confirmed fungal keratitis receive topical Natamycin drops for at least 48 hours. Then they are randomly assigned to one of three groups Cyclosporine A 0.1%, Cyclosporine A 2%, or placebo for four weeks. Natamycin treatment continues until the corneal ulcer has healed. The drops are used four times a day for one month, then twice daily for another month. This trial is conducted with cornea specialists at a hospital where fungal keratitis is common. Participants will have their best corrected vision tested at 12 weeks as the primary outcome. Other assessments include measuring corneal scar size, checking for corneal perforation, tracking ulcer healing, and confirming microbiologic cure. The study involves regular follow-ups to monitor healing and safety. Overall participation spans about three months, during which vision and eye health are carefully evaluated to understand the effects of the treatments.